Core Insights - The "Two Zones" initiative in Beijing has significantly improved the efficiency of clinical trials, reducing the average startup time to 24.9 weeks, with faster trials taking only 17.1 weeks, a reduction of 7.7 weeks year-on-year, facilitating the approval of 25 innovative drugs [1][3][4] Group 1: Clinical Trials and Research - The Beijing Health Commission has implemented reforms to enhance clinical research mechanisms, establishing a support system for clinical trials and launching 30 demonstration projects for research-oriented wards [3] - The initiative has alleviated the shortage of clinical trial beds, improving infrastructure and management efficiency, and compressing timelines for multi-center clinical research [3][4] Group 2: International Medical Services - The Beijing Health Commission is promoting foreign investment in the medical sector, with 52 medical institutions now having international medical departments, and 156 institutions providing full English services [4][5] - The city has launched an English version of the 114 appointment registration platform, facilitating access for foreign patients [5][6] Group 3: Innovative Pharmaceuticals - A collaborative policy framework has been established to expedite the entry of innovative drugs and medical devices into hospitals, involving multiple departments to streamline approval and procurement processes [6] - Major pharmaceutical companies are establishing R&D entities in Beijing, enhancing local collaboration and innovation in the healthcare sector [6] Group 4: Health Data Sharing - The Beijing Health Commission has initiated a plan for mutual recognition of medical examination results across institutions, covering 481 items, which enhances the efficiency of healthcare delivery [7][8] - The unified appointment registration platform now covers all secondary and tertiary medical institutions in Beijing, significantly increasing the volume of online queries for medical imaging and test results [8]